PMID- 15580918
OWN - NLM
STAT- MEDLINE
DCOM- 20041229
LR  - 20190713
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - 116
IP  - 5
DP  - 2004 Nov
TI  - Treatment update on spondyloarthropathy. From NSAIDs and DMARDs to anti-TNF-alpha 
      agents.
PG  - 31-6, 39-40
AB  - Traditionally, nonsteroidal anti-inflammatory drugs (NSAIDs) and 
      disease-modifying antirheumatic agents (DMARDs) have been used to control the 
      symptoms of spondyloarthropathy. With the advent of anti-tumor necrosis factor 
      alpha (anti-TNF-alpha) agents, however, it is now possible to slow disease 
      progression, improve overall function, and provide symptomatic relief of 
      arthritis, skin lesions, and bowel inflammation associated with these disorders. 
      Here, Drs Anandarajah and Ritchlin explore the effectiveness of conventional 
      therapies as well as biologic agents that are currently available or under 
      development.
FAU - Anandarajah, Allen P
AU  - Anandarajah AP
AD  - Department of Allergy, Immunology and Rheumatology, University of Rochester 
      School of Medicine and Dentistry, New York 14642, USA.
FAU - Ritchlin, Christopher T
AU  - Ritchlin CT
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
CIN - Postgrad Med. 2004 Nov;116(5):41-2, 48-50. PMID: 15580919
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Humans
MH  - Spondylarthropathies/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*therapeutic use
RF  - 20
EDAT- 2004/12/08 09:00
MHDA- 2004/12/30 09:00
CRDT- 2004/12/08 09:00
PHST- 2004/12/08 09:00 [pubmed]
PHST- 2004/12/30 09:00 [medline]
PHST- 2004/12/08 09:00 [entrez]
AID - 10.3810/pgm.2004.11.1609 [doi]
PST - ppublish
SO  - Postgrad Med. 2004 Nov;116(5):31-6, 39-40. doi: 10.3810/pgm.2004.11.1609.